{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:48:45Z","timestamp":1783385325190,"version":"3.54.6"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2008,2,12]]},"abstract":"<jats:p>\n            <jats:bold>\n              <jats:italic>Background\u2014<\/jats:italic>\n            <\/jats:bold>\n            Treatment of saphenous vein graft (SVG) stenosis with percutaneous coronary intervention has a 15% to 20% incidence of major adverse cardiac events (MACE) within 30 days. Although MACE rates are reduced significantly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefit provided by EPDs has been well characterized.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Methods and Results\u2014<\/jats:italic>\n            <\/jats:bold>\n            Data from 5 randomized controlled trials and 1 registry evaluating EPDs in SVG percutaneous coronary intervention (n=3958 patients) were pooled for analysis. MACE was defined as a composite of death, myocardial infarction, and target vessel revascularization. Baseline variables and 2 summary angiographic variables (an SVG degeneration score and an estimate of lesion plaque volume) were included in a multivariable logistic regression model to predict 30-day MACE, with adjustment for the type of device used and inter-study variation. The angiographic variables were potent predictors of MACE (increasing SVG degeneration score,\n            <jats:italic>P<\/jats:italic>\n            &lt;0.0001; larger estimated plaque volume,\n            <jats:italic>P<\/jats:italic>\n            &lt;0.0001), with significant contributions from the presence of thrombus (\n            <jats:italic>P<\/jats:italic>\n            &lt;0.01), increasing patient age (\n            <jats:italic>P<\/jats:italic>\n            &lt;0.01), glycoprotein IIb\/IIIa inhibitor use (\n            <jats:italic>P<\/jats:italic>\n            =0.02), and current tobacco abuse (\n            <jats:italic>P<\/jats:italic>\n            =0.03). The treatment benefit of EPDs was preserved across all categories of risk as categorized by SVG degeneration or plaque volume.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>\n              <jats:italic>Conclusions\u2014<\/jats:italic>\n            <\/jats:bold>\n            The strongest predictors of 30-day MACE in SVG percutaneous coronary intervention are angiographic estimates of plaque volume and SVG degeneration. Identification of these predictors of 30-day MACE allows reliable prediction of patient outcomes and confirms consistent treatment benefit with the use of EPDs across the range of patients tested in randomized trials.\n          <\/jats:p>","DOI":"10.1161\/circulationaha.106.651232","type":"journal-article","created":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T02:07:19Z","timestamp":1201054039000},"page":"790-797","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":118,"title":["Saphenous Vein Graft Stenting and Major Adverse Cardiac Events"],"prefix":"10.1161","volume":"117","author":[{"given":"Alanna","family":"Coolong","sequence":"first","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald S.","family":"Baim","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Kuntz","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. James","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Marulkar","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald E.","family":"Cutlip","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Popma","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[{"name":"From the Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Mass (A.C., L.M.); Boston Scientific, Natick, Mass (D.S.B.); Medtronic, Minneapolis, Minn (R.E.K.); and Department of Health Care Policy, Harvard Medical School (A.J.O.), Beth Israel-Deaconess Medical Center (D.E.C.), St Elizabeth\u2019s Medical Center (J.J.P.), and Harvard Clinical Research Institute (A.C., S.M., D.E.C., L.M.), Boston, Mass."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-7-199510010-00009"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.97.9.916"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(96)00206-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01324-9"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709113371103"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.100.24.2400"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.105.11.1285"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000080894.51311.0a"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.06.073"},{"key":"e_1_3_2_10_2","unstructured":"Dixon SR. Saphenous vein graft protection in a distal embolic protection randomized trial. Paper presented at: Transcatheter Cardiovascular Therapeutics; October 17 2005; Washington DC."},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.06.039"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.20465"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8183.2005.04063.x"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.08.090"},{"key":"e_1_3_2_15_2","first-page":"161","volume":"2","year":"2006","unstructured":"Holmes DR, Coolong A, O\u2019Shaughnessy C, Chauhan M, van Langenhove G, Hall P, Vermeersch P, Verlee P, Popma JJ, Cutlip DE, Kuntz RE. Comparison of the CardioShield filter with guardwire balloon in the prevention of embolisation during vein graft intervention; results from the CAPTIVE randomized trial. Eurointervention. 2006; 2: 161\u2013168.","journal-title":"Eurointervention"},{"key":"e_1_3_2_16_2","unstructured":"Cox DA. Stenting in saphenous vein grafts with distal protection using a second generation filter-based catheter: the combined BLAZE I and II registries. Paper presented at: Transcatheter Cardiovascular Therapeutics; October 17 2005; Washington DC."},{"key":"e_1_3_2_17_2","unstructured":"Lansky A Popma JJ. Qualitative and quantitative angiography. In: Topol EJ ed. Textbook of Interventional Cardiology. Philadelphia Pa: WB Saunders; 1999: 725\u2013747."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)90566-5"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)80410-X"},{"key":"e_1_3_2_20_2","first-page":"I-299.","volume":"88","year":"1993","unstructured":"Waksman R, Scott NA, Douglas JS Jr, Mays R, Yee-Petersen J, King SB 3rd. Distal embolization is common after directional atherectomy in coronary arteries and vein grafts. Circulation. 1993; 88 (suppl I): I-299. Abstract.","journal-title":"Circulation"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.101.5.570"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0304(199609)39:1<7::AID-CCD2>3.0.CO;2-A"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.89.6.8205658"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.92.4.734"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(97)70135-2"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(99)00196-5"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90366-9"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(93)90344-C"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90503-A"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(97)00280-5"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(89)90010-7"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(87)80075-X"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01420-6"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.105.551770"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.05.086"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00589-4"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000041250.89627.a9"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi736"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.09.001"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90712-A"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1337"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.106.651232","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:23:35Z","timestamp":1715574215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.106.651232"}},"subtitle":["A Predictive Model Derived From a Pooled Analysis of 3958 Patients"],"short-title":[],"issued":{"date-parts":[[2008,2,12]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,2,12]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.106.651232"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.106.651232","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,2,12]]},"assertion":[{"value":"2008-01-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}